Glenn Saldanha

Drug maker Glenmark Pharmaceuticals is counting on strong growth in the United States, where it will launch a dozen new medicines, to offset weakness in emerging markets this year, its chief executive said.

The company's board, which met today, has decided to raise funds by issuing upto 1.08 crore shares of Re 1 each for cash to Aranda Investments (Mauritius) Pte Ltd.

Glenmark Pharmaceuticals Ltd is in talks with foreign companies for a partnership on two of its biological drugs being tested for the treatment of chronic pain and autoimmune disorders, a senior executive said on Thursday.

Glenmark Pharmaceuticals on Thursday reported a 1.56 per cent dip in its consolidated net profit at Rs 154.29 crore for the quarter ended September 30, 2013 mainly on account of increased taxes.

Glenmark Pharmaceuticals on Tuesday posted a 10.93 per cent rise in its consolidated net profit at Rs 166.79 crore for its fourth quarter on the back of robust sales in both international and domestic markets.

Swiss companies are keenly looking at business opportunities in India and other high growth markets, amid sluggish economic conditions in Europe, a Swiss official said today.

J.P.Morgan says Glenmark is reporting "strong" growth outlook for its core markets of India and the United States, according to a report dated on Tuesday.

The pharmaceuticals company said its net profit rose to Rs 150.35 crore as compared to Rs 113.43 crore for the last financial year.

The company said it took a hit of Rs 102 crore on dollar denominated loans due to rupee depreciation.

Napo Pharmaceuticals Inc, however, had recently claimed terminating an agreement signed in July 2005 with Glenmark regarding Crofelemer.

Drug maker Glenmark Pharmaceuticals is counting on strong growth in the United States, where it will launch a dozen new medicines, to offset weakness in emerging markets this year, its chief executive said.

The company's board, which met today, has decided to raise funds by issuing upto 1.08 crore shares of Re 1 each for cash to Aranda Investments (Mauritius) Pte Ltd.

Glenmark Pharmaceuticals Ltd is in talks with foreign companies for a partnership on two of its biological drugs being tested for the treatment of chronic pain and autoimmune disorders, a senior executive said on Thursday.

Glenmark Pharmaceuticals on Thursday reported a 1.56 per cent dip in its consolidated net profit at Rs 154.29 crore for the quarter ended September 30, 2013 mainly on account of increased taxes.

Glenmark Pharmaceuticals on Tuesday posted a 10.93 per cent rise in its consolidated net profit at Rs 166.79 crore for its fourth quarter on the back of robust sales in both international and domestic markets.

Swiss companies are keenly looking at business opportunities in India and other high growth markets, amid sluggish economic conditions in Europe, a Swiss official said today.

J.P.Morgan says Glenmark is reporting "strong" growth outlook for its core markets of India and the United States, according to a report dated on Tuesday.

The pharmaceuticals company said its net profit rose to Rs 150.35 crore as compared to Rs 113.43 crore for the last financial year.

The company said it took a hit of Rs 102 crore on dollar denominated loans due to rupee depreciation.

Napo Pharmaceuticals Inc, however, had recently claimed terminating an agreement signed in July 2005 with Glenmark regarding Crofelemer.